Product training

We are pleased to present a new and improved version of the BD Veritor™ Plus System website. We have streamlined and cleaned up our site in order to better serve you, patients, and families. Take some time exploring as we hope you will refer to the site for all of your BD Veritor™ Plus System questions and needs.

The intended use of the BD Veritor™ System for Rapid Detection of SARS-CoV-2 assay only includes those who are suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms.

This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories
This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and
This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.